Dose modification guidelines for BIPN
| Severity of BIPN . | Action . |
|---|---|
| Grade 1 (paresthesias or areflexia without pain or loss of function) | Continue as scheduled |
| Grade 1 with pain or grade 2 (interferes with function but not with DLA) | Reduce dose per course to 1.0 mg/m2 |
| Grade 2 with pain or grade 3 (interferes with DLA) | Withhold bortezomib treatment until BIPN resolves, then reinitiate at a dose of 0.7 mg/m2 once weekly |
| Grade 4 (sensorimotor neuropathy that significantly interferes with DLA) | Discontinue therapy |
| Severity of BIPN . | Action . |
|---|---|
| Grade 1 (paresthesias or areflexia without pain or loss of function) | Continue as scheduled |
| Grade 1 with pain or grade 2 (interferes with function but not with DLA) | Reduce dose per course to 1.0 mg/m2 |
| Grade 2 with pain or grade 3 (interferes with DLA) | Withhold bortezomib treatment until BIPN resolves, then reinitiate at a dose of 0.7 mg/m2 once weekly |
| Grade 4 (sensorimotor neuropathy that significantly interferes with DLA) | Discontinue therapy |
BIPN indicates bortezomib-induced peripheral neuropathy; and DLA, daily living activities.